- October 31, 2018
Morning Rounds – Pilot study finds medical cannabis tied to lower opioid use in chronic nerve pain patients
Taking medical cannabis led 62 percent of patients with chronic nerve pain to cut down or stop their opioid use, according to a first-of-its-kind pilot study that tracked 76 individuals over nine months.
- October 29, 2018
ProQR licenses Ionis’ RNA drug for inherited blindness
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness. The plan is to start a phase 1/2 trial of the drug in 2019.
- October 28, 2018
Patrik De Haes, MD: What’s Coming Down the Retina Pipeline
At the 2018 American Academy of Ophthalmology Annual Meeting in Chicago, IL, Patrik De Haes, MD, CEO of Oxurion (formerly ThromboGenics) spoke about several investigational molecules his company is investigating for various retina conditions.
- October 22, 2018
Expansion of Medical Marijuana Legalization
Columbia Care is the largest multi-state medical cannabis operator in the United States. With a total of 33 licenses in 13 states, the company is looking to make an impact in the global cannabis industry by partnering with Canaccord Genuity Growth. Nicholas Vita, CEO and co-founder of Columbia Care, joins Cheddar to discuss.
- October 16, 2018
Columbia Care CEO on Canada cannabis legalization
Nicholas Vita, Columbia Care CEO, discusses how Canada’s legalization of recreational marijuana on Wednesday will affect the medicinal use market and how it may influence U.S.-based regulations.
- October 15, 2018
Krystal Gains on Early Data for Topical Gene Therapy in Skin Blistering Disease
Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa.
- October 15, 2018
This Biotech Has A Topical Gene Therapy — And Just Flew 30% On A Test
Krystal Biotech (KRYS) rocketed to a record high Monday after its gene therapy showed promise as a skin disease treatment. In midday trading on the stock market today, Krystal stock soared 30.9%, near 20.50. Earlier, Krystal popped as much as 37.6% in higher-than-average volume. Krystal stock began trading around 10 in September 2017.
- October 11, 2018
FR104 offers control of graft-versus-host disease
In a game-changing preclinical study targeted toward controlling graft-versus-host disease (GvHD), OSE Immunotherapeutics SA has shown new efficacy results evaluating FR104 and whether a transplant takes. This study, announced Aug. 22, showed strong evidence in the value of targeting CD28 in GvHD for potential clinical applications in autoimmune diseases and transplantation.
